



Clinical trial results:

A Combined Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Induction and Maintenance Study Evaluating the Safety and Efficacy of GS-5745 in Subjects with Moderately to Severely Active Ulcerative Colitis

Summary

| | |
|--------------------------|--|
| EudraCT number | 2014-005217-24 |
| Trial protocol | HU CZ SK BG GB AT DE BE NL LV SE ES IE IS HR |
| Global end of trial date | 22 November 2016 |

Results information

| | |
|--------------------------------|--|
| Result version number | v2 (current) |
| This version publication date | 25 March 2018 |
| First version publication date | 14 October 2017 |
| Version creation reason | <ul style="list-style-type: none">• Correction of full data set Added a justification in the Subject Disposition section and made a minor correction to the number of subjects in Andecaliximab Q2W arm who started in Period 3. |

Trial information

Trial identification

| | |
|-----------------------|----------------|
| Sponsor protocol code | GS-US-326-1100 |
|-----------------------|----------------|

Additional study identifiers

| | |
|------------------------------------|--|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT02520284 |
| WHO universal trial number (UTN) | - |
| Other trial identifiers | Clinical Trials Registry- India: CTRI/2016/09/007304 |

Notes:

Sponsors

| | |
|------------------------------|---|
| Sponsor organisation name | Gilead Sciences |
| Sponsor organisation address | 333 Lakeside Drive, Foster City, CA, United States, 94404 |
| Public contact | Clinical Trials Mailbox, Gilead Sciences International Ltd., ClinicalTrialDisclosures@gilead.com |
| Scientific contact | Clinical Trials Mailbox, Gilead Sciences International Ltd., ClinicalTrialDisclosures@gilead.com |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|------------------|
| Analysis stage | Final |
| Date of interim/final analysis | 22 November 2016 |
| Is this the analysis of the primary completion data? | No |
| Global end of trial reached? | Yes |
| Global end of trial date | 22 November 2016 |
| Was the trial ended prematurely? | Yes |

Notes:

General information about the trial

Main objective of the trial:

The primary objectives of this study were to evaluate the efficacy, safety, and tolerability of andecaliximab (GS-5745). This study was to consist of a sequential 2-part induction study (Cohort 1, Part A and Part B), a maintenance study (Cohort 2), and an optional extended treatment phase for participants who completed 52 weeks of treatment.

Protection of trial subjects:

The protocol and consent/assent forms were submitted by each investigator to a duly constituted Independent Ethics Committee (IEC) or Institutional Review Board (IRB) for review and approval before study initiation. All revisions to the consent/assent forms (if applicable) after initial IEC/IRB approval were submitted by the investigator to the IEC/IRB for review and approval before implementation in accordance with regulatory requirements.

This study was conducted in accordance with recognized international scientific and ethical standards, including but not limited to the International Conference on Harmonization guideline for Good Clinical Practice (ICH GCP) and the original principles embodied in the Declaration of Helsinki.

Background therapy: -

Evidence for comparator: -

| | |
|---|-------------------|
| Actual start date of recruitment | 15 September 2015 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|------------------------|
| Country: Number of subjects enrolled | Australia: 5 |
| Country: Number of subjects enrolled | Canada: 5 |
| Country: Number of subjects enrolled | Italy: 4 |
| Country: Number of subjects enrolled | New Zealand: 4 |
| Country: Number of subjects enrolled | South Africa: 2 |
| Country: Number of subjects enrolled | Switzerland: 2 |
| Country: Number of subjects enrolled | Taiwan: 1 |
| Country: Number of subjects enrolled | United States: 61 |
| Country: Number of subjects enrolled | Russian Federation: 10 |
| Country: Number of subjects enrolled | Ukraine: 9 |

| | |
|--------------------------------------|-----------------------|
| Country: Number of subjects enrolled | Netherlands: 1 |
| Country: Number of subjects enrolled | Poland: 23 |
| Country: Number of subjects enrolled | Romania: 7 |
| Country: Number of subjects enrolled | Slovakia: 1 |
| Country: Number of subjects enrolled | United Kingdom: 6 |
| Country: Number of subjects enrolled | Belgium: 6 |
| Country: Number of subjects enrolled | Bulgaria: 1 |
| Country: Number of subjects enrolled | Czech Republic: 2 |
| Country: Number of subjects enrolled | France: 1 |
| Country: Number of subjects enrolled | Hungary: 5 |
| Country: Number of subjects enrolled | Ireland: 1 |
| Country: Number of subjects enrolled | Latvia: 1 |
| Country: Number of subjects enrolled | Korea, Republic of: 7 |
| Worldwide total number of subjects | 165 |
| EEA total number of subjects | 59 |

Notes:

| Subjects enrolled per age group | |
|---|-----|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 152 |
| From 65 to 84 years | 13 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details:

Participants were enrolled at study sites in South Africa, Europe, North America, and Asia Pacific. The first participant was screened on 15 September 2015. The last study visit occurred on 22 November 2017.

Pre-assignment

Screening details:

241 participants were screened.

Period 1

| | |
|------------------------------|-------------------------|
| Period 1 title | Blinded Induction Phase |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator |

Arms

| | |
|------------------------------|-------------------|
| Are arms mutually exclusive? | Yes |
| Arm title | Andecaliximab Q2W |

Arm description:

Andecaliximab 150 mg subcutaneous (SC) injection once every 2 weeks (Q2W) for a total of 4 doses alternating with matching placebo every 2 weeks

| | |
|--|------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Andecaliximab |
| Investigational medicinal product code | GS-5745 |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

150 mg SC injection once every 2 weeks for a total of 4 doses

| | |
|--|------------------|
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Placebo SC injection once every 2 weeks

| | |
|------------------|------------------|
| Arm title | Andecaliximab QW |
|------------------|------------------|

Arm description:

Andecaliximab 150 mg subcutaneous injection once weekly (QW) for a total of 8 doses

| | |
|--|------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Andecaliximab |
| Investigational medicinal product code | GS-5745 |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

150 mg SC injection once every week for a total of 8 doses

| | |
|------------------|---------|
| Arm title | Placebo |
|------------------|---------|

Arm description:

Placebo SC injection once every week

| | |
|--|------------------|
| Arm type | Placebo |
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Placebo SC injection once every week

| Number of subjects in period 1 | Andecaliximab Q2W | Andecaliximab QW | Placebo |
|--------------------------------|-------------------|------------------|---------|
| Started | 54 | 56 | 55 |
| Completed | 52 | 52 | 53 |
| Not completed | 2 | 4 | 2 |
| Withdrew Consent | 1 | 1 | 1 |
| Adverse event, non-fatal | 1 | 3 | - |
| Study Terminated by Sponsor | - | - | 1 |

Period 2

| | |
|------------------------------|-------------------------------|
| Period 2 title | Blinded Maintenance Treatment |
| Is this the baseline period? | No |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator |

Arms

| | |
|------------------------------|-------------------|
| Are arms mutually exclusive? | Yes |
| Arm title | Andecaliximab Q2W |

Arm description:

Andecaliximab 150 mg SC injection once every 2 weeks for a total of 4 doses alternating with matching placebo every 2 weeks

| | |
|--|------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Andecaliximab |
| Investigational medicinal product code | GS-5745 |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

150 mg SC injection once every 2 weeks

| | |
|--|---------|
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |

| | |
|---|------------------|
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |
| Dosage and administration details: | |
| Placebo SC injection once every 2 weeks | |

| | |
|------------------|------------------|
| Arm title | Andecaliximab QW |
|------------------|------------------|

Arm description:

Andecaliximab 150 mg subcutaneous injection once weekly for a total of 8 doses

| | |
|--|------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Andecaliximab |
| Investigational medicinal product code | GS-5745 |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

150 mg SC injection once every week for a total of 8 doses

| | |
|------------------|---------|
| Arm title | Placebo |
|------------------|---------|

Arm description:

Placebo SC injection weekly

| | |
|--|------------------|
| Arm type | Placebo |
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Placebo SC injection once every week

| Number of subjects in period 2^[1] | Andecaliximab Q2W | Andecaliximab QW | Placebo |
|---|-------------------|------------------|---------|
| Started | 20 | 16 | 18 |
| Completed | 0 | 0 | 0 |
| Not completed | 20 | 16 | 18 |
| Adverse event, non-fatal | 1 | 1 | - |
| Disease Worsening | 2 | 2 | 3 |
| Study Terminated by Sponsor | 17 | 11 | 15 |
| Disposition Error | - | 2 | - |

Notes:

[1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: Only the participants who achieved EBS clinical remission and/or MCS response based on Week 8 assessments in the Blinding Induction Phase continued to the Blinding Maintenance Treatment. The remaining participants who met protocol specified disease worsening discontinuation criteria or did not achieve EBS clinical remission and/or MCS response, continued to the Open-Label Maintenance Phase.

Period 3

| | |
|------------------------------|------------------------------|
| Period 3 title | Open-Label Maintenance Phase |
| Is this the baseline period? | No |
| Allocation method | Non-randomised - controlled |
| Blinding used | Not blinded |

Arms

| | |
|------------------------------|--|
| Are arms mutually exclusive? | No |
| Arm title | Open-Label Andecaliximab QW from Andecaliximab Q2W |

Arm description:

Participants from the Andecaliximab Q2W group in the induction period, who did not achieve EBS clinical remission and/or MCS response based on Week 8 assessments (Week 8 nonresponders) received open-label andecaliximab 150 mg weekly for up to 51 weeks

| | |
|--|------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Andecaliximab |
| Investigational medicinal product code | GS-5745 |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

150 mg SC injection once every week for up to 51 weeks

| | |
|------------------|---|
| Arm title | Open-Label Andecaliximab QW from Andecaliximab QW |
|------------------|---|

Arm description:

Participants from the Andecaliximab QW group in the induction period, who did not achieve EBS clinical remission and/or MCS response based on Week 8 assessments (Week 8 nonresponders) received open-label andecaliximab 150 mg weekly for up to 51 weeks.

| | |
|--|------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Andecaliximab |
| Investigational medicinal product code | GS-5745 |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

150 mg SC injection once a week for up to 51 weeks

| | |
|------------------|--|
| Arm title | Open-Label Andecaliximab QW from Placebo |
|------------------|--|

Arm description:

Participants from the Placebo group in the induction period, who did not achieve EBS clinical remission and/or MCS response based on Week 8 assessments (Week 8 nonresponders) received open-label andecaliximab 150 mg weekly for up to 51 weeks.

| | |
|--|------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Andecaliximab |
| Investigational medicinal product code | GS-5745 |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

150 mg SC injection once every week for up to 51 weeks

| Number of subjects in period 3 | Open-Label Andecaliximab QW from Andecaliximab Q2W | Open-Label Andecaliximab QW from Andecaliximab QW | Open-Label Andecaliximab QW from Placebo |
|---------------------------------------|---|--|--|
| Started | 32 | 35 | 34 |
| Completed | 0 | 0 | 0 |
| Not completed | 32 | 35 | 34 |
| Withdrew Consent | 3 | 4 | 2 |
| Adverse event, non-fatal | 2 | 1 | 3 |
| Investigator's Discretion | 2 | 1 | 1 |
| Study Terminated by Sponsor | 25 | 29 | 28 |

Baseline characteristics

Reporting groups

| | |
|--|-------------------|
| Reporting group title | Andecaliximab Q2W |
| Reporting group description: Andecaliximab 150 mg subcutaneous (SC) injection once every 2 weeks (Q2W) for a total of 4 doses alternating with matching placebo every 2 weeks | |
| Reporting group title | Andecaliximab QW |
| Reporting group description: Andecaliximab 150 mg subcutaneous injection once weekly (QW) for a total of 8 doses | |
| Reporting group title | Placebo |
| Reporting group description: Placebo SC injection once every week | |

| Reporting group values | Andecaliximab Q2W | Andecaliximab QW | Placebo |
|------------------------|-------------------|------------------|---------|
| Number of subjects | 54 | 56 | 55 |
| Age categorical | | | |
| Units: Subjects | | | |

| | | | |
|--|--------|--------|--------|
| Age continuous | | | |
| Safety Analysis Set includes all participants who took at least 1 dose of study drug in the Induction Study. | | | |
| Units: years | | | |
| arithmetic mean | 44 | 43 | 43 |
| standard deviation | ± 14.1 | ± 13.2 | ± 12.8 |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 19 | 18 | 24 |
| Male | 35 | 38 | 31 |
| Race | | | |
| Units: Subjects | | | |
| White | 48 | 48 | 45 |
| Black | 4 | 3 | 3 |
| Asian | 2 | 4 | 4 |
| Native Hawaiian or Pacific | 0 | 0 | 1 |
| Not Permitted | 0 | 0 | 1 |
| Other | 0 | 1 | 1 |
| Ethnicity | | | |
| Units: Subjects | | | |
| Hispanic or Latino | 0 | 0 | 2 |
| Not Hispanic or Latino | 54 | 56 | 51 |
| Not Permitted | 0 | 0 | 2 |

| Reporting group values | Total | | |
|------------------------|-------|--|--|
| Number of subjects | 165 | | |
| Age categorical | | | |
| Units: Subjects | | | |

| | | | |
|--|-----|--|--|
| Age continuous | | | |
| Safety Analysis Set includes all participants who took at least 1 dose of study drug in the Induction Study. | | | |
| Units: years arithmetic mean standard deviation | - | | |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 61 | | |
| Male | 104 | | |
| Race | | | |
| Units: Subjects | | | |
| White | 141 | | |
| Black | 10 | | |
| Asian | 10 | | |
| Native Hawaiian or Pacific | 1 | | |
| Not Permitted | 1 | | |
| Other | 2 | | |
| Ethnicity | | | |
| Units: Subjects | | | |
| Hispanic or Latino | 2 | | |
| Not Hispanic or Latino | 161 | | |
| Not Permitted | 2 | | |

End points

End points reporting groups

| | |
|---|--|
| Reporting group title | Andecaliximab Q2W |
| Reporting group description: Andecaliximab 150 mg subcutaneous (SC) injection once every 2 weeks (Q2W) for a total of 4 doses alternating with matching placebo every 2 weeks | |
| Reporting group title | Andecaliximab QW |
| Reporting group description: Andecaliximab 150 mg subcutaneous injection once weekly (QW) for a total of 8 doses | |
| Reporting group title | Placebo |
| Reporting group description: Placebo SC injection once every week | |
| Reporting group title | Andecaliximab Q2W |
| Reporting group description: Andecaliximab 150 mg SC injection once every 2 weeks for a total of 4 doses alternating with matching placebo every 2 weeks | |
| Reporting group title | Andecaliximab QW |
| Reporting group description: Andecaliximab 150 mg subcutaneous injection once weekly for a total of 8 doses | |
| Reporting group title | Placebo |
| Reporting group description: Placebo SC injection weekly | |
| Reporting group title | Open-Label Andecaliximab QW from Andecaliximab Q2W |
| Reporting group description: Participants from the Andecaliximab Q2W group in the induction period, who did not achieve EBS clinical remission and/or MCS response based on Week 8 assessments (Week 8 nonresponders) received open-label andecaliximab 150 mg weekly for up to 51 weeks | |
| Reporting group title | Open-Label Andecaliximab QW from Andecaliximab QW |
| Reporting group description: Participants from the Andecaliximab QW group in the induction period, who did not achieve EBS clinical remission and/or MCS response based on Week 8 assessments (Week 8 nonresponders) received open-label andecaliximab 150 mg weekly for up to 51 weeks. | |
| Reporting group title | Open-Label Andecaliximab QW from Placebo |
| Reporting group description: Participants from the Placebo group in the induction period, who did not achieve EBS clinical remission and/or MCS response based on Week 8 assessments (Week 8 nonresponders) received open-label andecaliximab 150 mg weekly for up to 51 weeks. | |

Primary: For Cohort 1, percentage of participants with endoscopy, rectal bleeding, and stool frequency (EBS) Clinical Remission at Week 8

| | |
|---|---|
| End point title | For Cohort 1, percentage of participants with endoscopy, rectal bleeding, and stool frequency (EBS) Clinical Remission at Week 8 ^[1] |
| End point description: EBS clinical remission was defined as an endoscopic subscore of 0 or 1, rectal bleeding subscore of 0, and at least a one point decrease in stool frequency from baseline to achieve a subscore of 0 or 1. Full Analysis Set: all randomized participants who take at least 1 dose of study drug in the Induction Study (Cohort 1). | |
| End point type | Primary |
| End point timeframe: Week 8 | |

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due to termination of the study, no statistical comparison was performed.

| End point values | Andecaliximab Q2W | Andecaliximab QW | Placebo | |
|-----------------------------------|-------------------|------------------|-----------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 54 | 56 | 55 | |
| Units: Percentage of participants | | | | |
| number (confidence interval 95%) | 7.4 (2.1 to 17.9) | 1.8 (0 to 9.6) | 7.3 (2 to 17.6) | |

Statistical analyses

No statistical analyses for this end point

Secondary: For Cohort 1, percentage of participants with Mayo Clinic Score (MCS) Remission at Week 8

| | |
|-----------------|---|
| End point title | For Cohort 1, percentage of participants with Mayo Clinic Score (MCS) Remission at Week 8 |
|-----------------|---|

End point description:

1) Mayo clinic score was composed of subscores from endoscopy, rectal bleeding, stool frequency, and PGA. Mayo clinic score remission was defined as a MCS of ≤ 2 points and no individual subscore > 1 point.

2) Full Analysis Set

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 8

| End point values | Andecaliximab Q2W | Andecaliximab QW | Placebo | |
|-----------------------------------|-------------------|------------------|-----------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 54 | 56 | 55 | |
| Units: Percentage of participants | | | | |
| number (not applicable) | 7.4 | 1.8 | 7.3 | |

Statistical analyses

No statistical analyses for this end point

Secondary: For Cohort 1, percentage of participants achieving MCS response at Week 8

| | |
|-----------------|---|
| End point title | For Cohort 1, percentage of participants achieving MCS response at Week 8 |
|-----------------|---|

End point description:

1) Mayo clinic score response was defined as a MCS reduction of ≥ 3 points and at least 30% from

baseline, with an accompanying decrease in rectal bleeding subscore of ≥ 1 point or an absolute rectal bleeding subscore of 0 or 1.

2) Full Analysis Set

| | |
|----------------------|-----------|
| End point type | Secondary |
| End point timeframe: | |
| Week 8 | |

| End point values | Andecaliximab Q2W | Andecaliximab QW | Placebo | |
|-----------------------------------|-------------------|------------------|-----------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 54 | 56 | 55 | |
| Units: Percentage of participants | | | | |
| number (not applicable) | 46.3 | 30.4 | 30.9 | |

Statistical analyses

No statistical analyses for this end point

Secondary: For Cohort 1, percentage of participants achieving endoscopic remission (endoscopic subscore of 0) at Week 8

| | |
|--|--|
| End point title | For Cohort 1, percentage of participants achieving endoscopic remission (endoscopic subscore of 0) at Week 8 |
| End point description: | |
| Endoscopic remission was defined as an endoscopic subscore of 0. | |
| End point type | Secondary |
| End point timeframe: | |
| Week 8 | |

| End point values | Andecaliximab Q2W | Andecaliximab QW | Placebo | |
|-----------------------------------|-------------------|------------------|-----------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 54 | 56 | 55 | |
| Units: Percentage of participants | | | | |
| number (not applicable) | 3.7 | 0 | 5.5 | |

Statistical analyses

No statistical analyses for this end point

Secondary: For Cohort 1, percentage of participants achieving endoscopic response (endoscopic subscore 0 or 1) at Week 8

| | |
|-----------------|---|
| End point title | For Cohort 1, percentage of participants achieving endoscopic response (endoscopic subscore 0 or 1) at Week 8 |
|-----------------|---|

End point description:

- 1) Endoscopic response was defined as an endoscopic subscore of 0 or 1.
- 2) Full analysis Set

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 8

| End point values | Andecaliximab Q2W | Andecaliximab QW | Placebo | |
|-----------------------------------|-------------------|------------------|-----------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 54 | 56 | 55 | |
| Units: Percentage of participants | | | | |
| number (not applicable) | 18.5 | 7.1 | 14.5 | |

Statistical analyses

No statistical analyses for this end point

Secondary: For Cohort 1: percentage of participants achieving mucosal healing as determined by the Geboes histologic scoring system at Week 8

| | |
|-----------------|--|
| End point title | For Cohort 1: percentage of participants achieving mucosal healing as determined by the Geboes histologic scoring system at Week 8 |
|-----------------|--|

End point description:

- 1) Mucosal healing was defined as elimination of ulcers/erosion, elimination of crypt destruction, elimination of intraepithelial neutrophils, elimination of lamina propria neutrophils, and reduction in lamina propria chronic inflammatory cells to at most a mild increase. When measured by the Geboes histologic scoring system, it was the selection of the following combined scores of ≤ 3 for Grade 0 (Structural Architectural Change), ≤ 1 for Grade 1 (Chronic Inflammatory Infiltrate), ≤ 3 for Grade 2A (Lamina Propria Eosinophils), and 0 for Grade 2B (Lamina Propria Neutrophils), Grade 3 (Neutrophils in Epithelium), Grade 4 (Crypt Destruction), and Grade 5 (Erosion or Ulceration).
- 2) Full Analysis Set
- 3) For calculating the percentage of participants achieving mucosal healing as determined by Geboes histologic scoring system, only participants who did not meet the mucosal healing definition at baseline were included.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 8

| End point values | Andecaliximab Q2W | Andecaliximab QW | Placebo | |
|-----------------------------------|-------------------|------------------|-----------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 50 | 51 | 50 | |
| Units: Percentage of participants | | | | |
| number (not applicable) | 18 | 13.7 | 22 | |

Statistical analyses

No statistical analyses for this end point

Secondary: For Cohort 1: percentage of participants achieving remission as defined by MCS remission (alternative definition) at Week 8

| | |
|-----------------|---|
| End point title | For Cohort 1: percentage of participants achieving remission as defined by MCS remission (alternative definition) at Week 8 |
|-----------------|---|

End point description:

1) Mayo clinic score remission (alternative definition) was defined as a rectal bleeding, stool frequency, and PGA subscore of 0, and an endoscopic subscore of 0 or 1 for an overall MCS of ≤ 1 .

2) Full Analysis Set

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 8

| End point values | Andecaliximab Q2W | Andecaliximab QW | Placebo | |
|--------------------------------|----------------------|---------------------|-----------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 54 | 56 | 55 | |
| Units: Percentage participants | | | | |
| number (not applicable) | 1.9 | 0 | 0 | |

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Induction Period: First dose of andecaliximab to Week 8;

Double-Blind (DB) Period: First dose of andecaliximab to Week 52 plus 30 days;

Open-Label (OL) Period: First dose of open-label andecaliximab to Week 52 plus 30 days

Adverse event reporting additional description:

Safety data in general was summarized by the following analysis periods by treatment group: 1.

Induction Period (All Subjects) 2. DB Treatment Period (Wk 8 Responders; included safety data collected for these subjects between Week 0 and Wk 8 in the induction period, as well as the DB maintenance phase) 3. OL Maintenance Period (Wk 8 Nonresponders)

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 19.1 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|-----------------------------|
| Reporting group title | Induction Andecaliximab Q2W |
|-----------------------|-----------------------------|

Reporting group description:

1) Andecaliximab 150 mg SC injection once every 2 weeks for a total of 4 doses

2) Adverse events (AE) reported in this group occurred during the Induction with Additional Dose Period (Baseline to Week 8): any AEs with an onset date on or after the induction study start date and no later than 30 days after permanent discontinuation of study drug if discontinued in this period, any AEs with an onset date on or after the induction study start date and before Week 9 dosing date and no later than 30 days after the Week 8 additional dosing date, and any AEs leading to premature discontinuation.

| | |
|-----------------------|----------------------------|
| Reporting group title | Induction Andecaliximab QW |
|-----------------------|----------------------------|

Reporting group description:

1) Andecaliximab 150 mg SC injection once every week for a total of 8 doses

2) Adverse events reported in this group occurred during the Induction with Additional Dose Period (Baseline to Week 8): any AEs with an onset date on or after the induction study start date and no later than 30 days after permanent discontinuation of study drug if discontinued in this period, any AEs with an onset date on or after the induction study start date and before Week 9 dosing date and no later than 30 days after the Week 8 additional dosing date, and any AEs leading to premature discontinuation.

| | |
|-----------------------|-------------------|
| Reporting group title | Induction Placebo |
|-----------------------|-------------------|

Reporting group description:

1) Placebo SC injection once every week up to 8 weeks

2) Adverse events (AE) reported in this group occurred during the Induction with Additional Dose Period (Baseline to Week 8): any AEs with an onset date on or after the induction study start date and no later than 30 days after permanent discontinuation of study drug if discontinued in this period, any AEs with an onset date on or after the induction study start date and before Week 9 dosing date and no later than 30 days after the Week 8 additional dosing date, and any AEs leading to premature discontinuation.

| | |
|-----------------------|--|
| Reporting group title | Double-Blind Maintenance Andecaliximab Q2W |
|-----------------------|--|

Reporting group description:

1) Andecaliximab 150 mg SC injection once every 2 weeks for up to 52 weeks

2) Adverse events reported in this group occurred during the Induction or Double-Blind Periods (Baseline to Week 52 plus 30 days): any AEs with an onset date on or after the double-blinded study drug start date and no later than EITHER 30 days after permanent discontinuation of double-blinded study drug if not switched to OL treatment, OR the first dose date of OL dose if switched.

| | |
|-----------------------|---|
| Reporting group title | Double-Blind Maintenance Andecaliximab QW |
|-----------------------|---|

Reporting group description:

1) Andecaliximab 150 mg subcutaneous injection once every week for up to 52 weeks

2) Adverse events reported in this group occurred during the Induction or Double-Blind Periods (Baseline to Week 52 plus 30 days): any AEs with an onset date on or after the double-blinded study drug start date and no later than EITHER 30 days after permanent discontinuation of double-blinded study drug if not switched to OL treatment, OR the first dose date of OL dose if switched.

| | |
|-----------------------|----------------------------------|
| Reporting group title | Double-Blind Maintenance Placebo |
|-----------------------|----------------------------------|

Reporting group description:

- 1) Placebo SC injection once every week for up to 52 weeks
- 2) Adverse events reported in this group occurred during the Induction or Double-Blind Periods (Baseline to Week 52 plus 30 days): any AEs with an onset date on or after the double-blinded study drug start date and no later than EITHER 30 days after permanent discontinuation of double-blinded study drug if not switched to OL treatment, OR the first dose date of OL dose if switched

| | |
|-----------------------|--|
| Reporting group title | Open-Label Andecaliximab QW from Andecaliximab Q2W |
|-----------------------|--|

Reporting group description:

- 1) Participants from the Andecaliximab Q2W group in the induction period, who switched to open-label treatment after Week 8 assessment and received open-label andecaliximab 150 mg weekly up to 51 weeks.
- 2) Adverse events reported in this group occurred during the Open-Label Period (Study drug start during open-label to Week 52 plus 30 days): any AEs with an onset date on or after the open-label study drug start date and no later than 30 days after permanent discontinuation of open-label study drug.

| | |
|-----------------------|---|
| Reporting group title | Open-Label Andecaliximab QW from Andecaliximab QW |
|-----------------------|---|

Reporting group description:

- 1) Participants from the Andecaliximab QW group in the induction period, who switched to open-label treatment after Week 8 assessment and received open-label andecaliximab 150 mg weekly up to 51 weeks.
- 2) Adverse events for Open-Label Period (Study drug start during open-label to Week 52 plus 30 days) were any AEs with an onset date on or after the open-label study drug start date and no later than 30 days after permanent discontinuation of open-label study drug.

| | |
|-----------------------|--|
| Reporting group title | Open-Label Andecaliximab QW from Placebo |
|-----------------------|--|

Reporting group description:

- 1) Participants from the placebo group in the induction period, who switched to open-label treatment after Week 8 assessment and received open-label andecaliximab 150 mg weekly up to 51 weeks.
- 2) Adverse events for Open-Label Period (Study drug start during open-label to Week 52 plus 30 days) were any AEs with an onset date on or after the open-label study drug start date and no later than 30 days after permanent discontinuation of open-label study drug.

| Serious adverse events | Induction Andecaliximab Q2W | Induction Andecaliximab QW | Induction Placebo |
|---|-----------------------------|----------------------------|-------------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 0 / 54 (0.00%) | 2 / 56 (3.57%) | 1 / 55 (1.82%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | | | |
| Cardiac disorders | | | |
| Angina pectoris | | | |
| subjects affected / exposed | 0 / 54 (0.00%) | 1 / 56 (1.79%) | 0 / 55 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| Cerebrovascular accident | | | |
| subjects affected / exposed | 0 / 54 (0.00%) | 0 / 56 (0.00%) | 0 / 55 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |

| | | | |
|---|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 54 (0.00%) | 1 / 56 (1.79%) | 0 / 55 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Colitis ulcerative | | | |
| subjects affected / exposed | 0 / 54 (0.00%) | 0 / 56 (0.00%) | 0 / 55 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Inguinal hernia | | | |
| subjects affected / exposed | 0 / 54 (0.00%) | 0 / 56 (0.00%) | 0 / 55 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| Biliary dilatation | | | |
| subjects affected / exposed | 0 / 54 (0.00%) | 0 / 56 (0.00%) | 0 / 55 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| Nephrolithiasis | | | |
| subjects affected / exposed | 0 / 54 (0.00%) | 0 / 56 (0.00%) | 0 / 55 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Anal abscess | | | |
| subjects affected / exposed | 0 / 54 (0.00%) | 0 / 56 (0.00%) | 1 / 55 (1.82%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cytomegalovirus infection | | | |
| subjects affected / exposed | 0 / 54 (0.00%) | 0 / 56 (0.00%) | 0 / 55 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| Serious adverse events | Double-Blind Maintenance Anecaliximab Q2W | Double-Blind Maintenance Anecaliximab QW | Double-Blind Maintenance Placebo |
|---|---|--|-------------------------------------|
| Total subjects affected by serious adverse events | | | |

| | | | |
|---|----------------|-----------------|----------------|
| subjects affected / exposed | 1 / 20 (5.00%) | 2 / 16 (12.50%) | 1 / 18 (5.56%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | | | |
| Cardiac disorders | | | |
| Angina pectoris | | | |
| subjects affected / exposed | 0 / 20 (0.00%) | 1 / 16 (6.25%) | 0 / 18 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| Cerebrovascular accident | | | |
| subjects affected / exposed | 0 / 20 (0.00%) | 0 / 16 (0.00%) | 0 / 18 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 0 / 20 (0.00%) | 0 / 16 (0.00%) | 0 / 18 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Colitis ulcerative | | | |
| subjects affected / exposed | 1 / 20 (5.00%) | 0 / 16 (0.00%) | 0 / 18 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Inguinal hernia | | | |
| subjects affected / exposed | 0 / 20 (0.00%) | 1 / 16 (6.25%) | 0 / 18 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| Biliary dilatation | | | |
| subjects affected / exposed | 0 / 20 (0.00%) | 0 / 16 (0.00%) | 0 / 18 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| Nephrolithiasis | | | |

| | | | |
|---|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 20 (0.00%) | 0 / 16 (0.00%) | 0 / 18 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Anal abscess | | | |
| subjects affected / exposed | 0 / 20 (0.00%) | 0 / 16 (0.00%) | 1 / 18 (5.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cytomegalovirus infection | | | |
| subjects affected / exposed | 0 / 20 (0.00%) | 0 / 16 (0.00%) | 0 / 18 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| Serious adverse events | Open-Label Andecaliximab QW from Andecaliximab Q2W | Open-Label Andecaliximab QW from Andecaliximab QW | Open-Label Andecaliximab QW from Placebo |
|--|---|--|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 1 / 32 (3.13%) | 3 / 35 (8.57%) | 2 / 34 (5.88%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | | | |
| Cardiac disorders | | | |
| Angina pectoris | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 0 / 34 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| Cerebrovascular accident | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 1 / 34 (2.94%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 0 / 34 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |

| | | | |
|---|----------------|----------------|----------------|
| Colitis ulcerative | | | |
| subjects affected / exposed | 1 / 32 (3.13%) | 1 / 35 (2.86%) | 1 / 34 (2.94%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Inguinal hernia | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 0 / 34 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| Biliary dilatation | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 1 / 34 (2.94%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| Nephrolithiasis | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 1 / 35 (2.86%) | 0 / 34 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Anal abscess | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 0 / 34 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cytomegalovirus infection | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 1 / 35 (2.86%) | 0 / 34 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

Frequency threshold for reporting non-serious adverse events: 5 %

| Non-serious adverse events | Induction Andecaliximab Q2W | Induction Andecaliximab QW | Induction Placebo |
|---|--------------------------------|-------------------------------|-------------------|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 24 / 54 (44.44%) | 31 / 56 (55.36%) | 26 / 55 (47.27%) |
| Vascular disorders | | | |

| | | | |
|---|---------------------|---------------------|---------------------|
| Hypertension subjects affected / exposed occurrences (all) | 0 / 54 (0.00%) 0 | 1 / 56 (1.79%) 1 | 0 / 55 (0.00%) 0 |
| General disorders and administration site conditions | | | |
| Fatigue subjects affected / exposed occurrences (all) | 1 / 54 (1.85%) 1 | 1 / 56 (1.79%) 1 | 3 / 55 (5.45%) 3 |
| Feeling hot subjects affected / exposed occurrences (all) | 0 / 54 (0.00%) 0 | 0 / 56 (0.00%) 0 | 1 / 55 (1.82%) 1 |
| Influenza like illness subjects affected / exposed occurrences (all) | 0 / 54 (0.00%) 0 | 0 / 56 (0.00%) 0 | 1 / 55 (1.82%) 1 |
| Injection site bruising subjects affected / exposed occurrences (all) | 1 / 54 (1.85%) 2 | 4 / 56 (7.14%) 4 | 0 / 55 (0.00%) 0 |
| Injection site erythema subjects affected / exposed occurrences (all) | 0 / 54 (0.00%) 0 | 1 / 56 (1.79%) 1 | 0 / 55 (0.00%) 0 |
| Injection site hypersensitivity subjects affected / exposed occurrences (all) | 1 / 54 (1.85%) 1 | 0 / 56 (0.00%) 0 | 0 / 55 (0.00%) 0 |
| Peripheral swelling subjects affected / exposed occurrences (all) | 0 / 54 (0.00%) 0 | 0 / 56 (0.00%) 0 | 1 / 55 (1.82%) 1 |
| Pyrexia subjects affected / exposed occurrences (all) | 1 / 54 (1.85%) 1 | 4 / 56 (7.14%) 4 | 1 / 55 (1.82%) 1 |
| Thirst subjects affected / exposed occurrences (all) | 0 / 54 (0.00%) 0 | 0 / 56 (0.00%) 0 | 0 / 55 (0.00%) 0 |
| Immune system disorders | | | |
| Hypersensitivity subjects affected / exposed occurrences (all) | 0 / 54 (0.00%) 0 | 0 / 56 (0.00%) 0 | 0 / 55 (0.00%) 0 |
| Reproductive system and breast disorders | | | |

| | | | |
|--|---------------------|---------------------|---------------------|
| Menstrual disorder subjects affected / exposed occurrences (all) | 0 / 54 (0.00%) 0 | 0 / 56 (0.00%) 0 | 0 / 55 (0.00%) 0 |
| Uterine prolapse subjects affected / exposed occurrences (all) | 0 / 54 (0.00%) 0 | 1 / 56 (1.79%) 1 | 0 / 55 (0.00%) 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Cough subjects affected / exposed occurrences (all) | 1 / 54 (1.85%) 1 | 3 / 56 (5.36%) 3 | 1 / 55 (1.82%) 1 |
| Dyspnoea subjects affected / exposed occurrences (all) | 0 / 54 (0.00%) 0 | 1 / 56 (1.79%) 1 | 0 / 55 (0.00%) 0 |
| Upper respiratory tract inflammation subjects affected / exposed occurrences (all) | 1 / 54 (1.85%) 1 | 0 / 56 (0.00%) 0 | 0 / 55 (0.00%) 0 |
| Psychiatric disorders | | | |
| Depression subjects affected / exposed occurrences (all) | 1 / 54 (1.85%) 1 | 0 / 56 (0.00%) 0 | 1 / 55 (1.82%) 1 |
| Investigations | | | |
| Blood creatine phosphokinase increased subjects affected / exposed occurrences (all) | 1 / 54 (1.85%) 1 | 0 / 56 (0.00%) 0 | 2 / 55 (3.64%) 2 |
| Haemoglobin decreased subjects affected / exposed occurrences (all) | 0 / 54 (0.00%) 0 | 0 / 56 (0.00%) 0 | 0 / 55 (0.00%) 0 |
| Lymphocyte count decreased subjects affected / exposed occurrences (all) | 1 / 54 (1.85%) 1 | 0 / 56 (0.00%) 0 | 0 / 55 (0.00%) 0 |
| Hypophosphataemia subjects affected / exposed occurrences (all) | 0 / 54 (0.00%) 0 | 1 / 56 (1.79%) 1 | 0 / 55 (0.00%) 0 |
| Iron deficiency subjects affected / exposed occurrences (all) | 1 / 54 (1.85%) 1 | 1 / 56 (1.79%) 1 | 0 / 55 (0.00%) 0 |

| | | | |
|--|----------------|----------------|----------------|
| Injury, poisoning and procedural complications | | | |
| Injection related reaction | | | |
| subjects affected / exposed | 0 / 54 (0.00%) | 0 / 56 (0.00%) | 2 / 55 (3.64%) |
| occurrences (all) | 0 | 0 | 2 |
| Radius fracture | | | |
| subjects affected / exposed | 1 / 54 (1.85%) | 0 / 56 (0.00%) | 1 / 55 (1.82%) |
| occurrences (all) | 1 | 0 | 1 |
| Nervous system disorders | | | |
| Dizziness | | | |
| subjects affected / exposed | 0 / 54 (0.00%) | 1 / 56 (1.79%) | 1 / 55 (1.82%) |
| occurrences (all) | 0 | 1 | 1 |
| Headache | | | |
| subjects affected / exposed | 2 / 54 (3.70%) | 4 / 56 (7.14%) | 1 / 55 (1.82%) |
| occurrences (all) | 3 | 4 | 1 |
| Lethargy | | | |
| subjects affected / exposed | 0 / 54 (0.00%) | 0 / 56 (0.00%) | 1 / 55 (1.82%) |
| occurrences (all) | 0 | 0 | 1 |
| Polyneuropathy | | | |
| subjects affected / exposed | 0 / 54 (0.00%) | 1 / 56 (1.79%) | 0 / 55 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Sciatica | | | |
| subjects affected / exposed | 0 / 54 (0.00%) | 0 / 56 (0.00%) | 0 / 55 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 4 / 54 (7.41%) | 4 / 56 (7.14%) | 2 / 55 (3.64%) |
| occurrences (all) | 4 | 4 | 2 |
| Thrombocytosis | | | |
| subjects affected / exposed | 0 / 54 (0.00%) | 0 / 56 (0.00%) | 0 / 55 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ear and labyrinth disorders | | | |
| Ear discomfort | | | |
| subjects affected / exposed | 0 / 54 (0.00%) | 0 / 56 (0.00%) | 0 / 55 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye disorders | | | |

| | | | |
|-----------------------------|----------------|----------------|----------------|
| Dry eye | | | |
| subjects affected / exposed | 0 / 54 (0.00%) | 0 / 56 (0.00%) | 0 / 55 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrointestinal disorders | | | |
| Abdominal discomfort | | | |
| subjects affected / exposed | 0 / 54 (0.00%) | 0 / 56 (0.00%) | 1 / 55 (1.82%) |
| occurrences (all) | 0 | 0 | 1 |
| Abdominal distension | | | |
| subjects affected / exposed | 0 / 54 (0.00%) | 1 / 56 (1.79%) | 1 / 55 (1.82%) |
| occurrences (all) | 0 | 1 | 2 |
| Abdominal pain | | | |
| subjects affected / exposed | 1 / 54 (1.85%) | 2 / 56 (3.57%) | 5 / 55 (9.09%) |
| occurrences (all) | 1 | 2 | 5 |
| Colitis ulcerative | | | |
| subjects affected / exposed | 2 / 54 (3.70%) | 3 / 56 (5.36%) | 1 / 55 (1.82%) |
| occurrences (all) | 2 | 3 | 1 |
| Dyschezia | | | |
| subjects affected / exposed | 0 / 54 (0.00%) | 1 / 56 (1.79%) | 0 / 55 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Frequent bowel movements | | | |
| subjects affected / exposed | 0 / 54 (0.00%) | 0 / 56 (0.00%) | 1 / 55 (1.82%) |
| occurrences (all) | 0 | 0 | 1 |
| Haematochezia | | | |
| subjects affected / exposed | 1 / 54 (1.85%) | 0 / 56 (0.00%) | 1 / 55 (1.82%) |
| occurrences (all) | 1 | 1 | 1 |
| Haemorrhoids | | | |
| subjects affected / exposed | 0 / 54 (0.00%) | 0 / 56 (0.00%) | 0 / 55 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Inguinal hernia | | | |
| subjects affected / exposed | 0 / 54 (0.00%) | 0 / 56 (0.00%) | 0 / 55 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mouth ulceration | | | |
| subjects affected / exposed | 2 / 54 (3.70%) | 2 / 56 (3.57%) | 0 / 55 (0.00%) |
| occurrences (all) | 2 | 2 | 0 |
| Nausea | | | |

| | | | |
|--|----------------|----------------|----------------|
| subjects affected / exposed | 2 / 54 (3.70%) | 3 / 56 (5.36%) | 3 / 55 (5.45%) |
| occurrences (all) | 2 | 3 | 3 |
| Rectal haemorrhage | | | |
| subjects affected / exposed | 1 / 54 (1.85%) | 0 / 56 (0.00%) | 0 / 55 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Skin and subcutaneous tissue disorders | | | |
| Acne | | | |
| subjects affected / exposed | 0 / 54 (0.00%) | 1 / 56 (1.79%) | 0 / 55 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Alopecia | | | |
| subjects affected / exposed | 0 / 54 (0.00%) | 1 / 56 (1.79%) | 0 / 55 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Dry skin | | | |
| subjects affected / exposed | 1 / 54 (1.85%) | 0 / 56 (0.00%) | 1 / 55 (1.82%) |
| occurrences (all) | 1 | 0 | 1 |
| Erythema | | | |
| subjects affected / exposed | 0 / 54 (0.00%) | 2 / 56 (3.57%) | 0 / 55 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Erythema nodosum | | | |
| subjects affected / exposed | 0 / 54 (0.00%) | 0 / 56 (0.00%) | 0 / 55 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Night sweats | | | |
| subjects affected / exposed | 1 / 54 (1.85%) | 1 / 56 (1.79%) | 0 / 55 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Onychoclasia | | | |
| subjects affected / exposed | 0 / 54 (0.00%) | 1 / 56 (1.79%) | 0 / 55 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Psoriasis | | | |
| subjects affected / exposed | 0 / 54 (0.00%) | 1 / 56 (1.79%) | 0 / 55 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Rash | | | |
| subjects affected / exposed | 1 / 54 (1.85%) | 0 / 56 (0.00%) | 0 / 55 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Skin lesion | | | |
| subjects affected / exposed | 0 / 54 (0.00%) | 1 / 56 (1.79%) | 1 / 55 (1.82%) |
| occurrences (all) | 0 | 1 | 1 |

| | | | |
|---|----------------|----------------|----------------|
| Renal and urinary disorders | | | |
| Haematuria | | | |
| subjects affected / exposed | 0 / 54 (0.00%) | 0 / 56 (0.00%) | 0 / 55 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 1 / 54 (1.85%) | 3 / 56 (5.36%) | 3 / 55 (5.45%) |
| occurrences (all) | 1 | 3 | 3 |
| Back pain | | | |
| subjects affected / exposed | 1 / 54 (1.85%) | 3 / 56 (5.36%) | 2 / 55 (3.64%) |
| occurrences (all) | 1 | 3 | 2 |
| Muscle spasms | | | |
| subjects affected / exposed | 0 / 54 (0.00%) | 1 / 56 (1.79%) | 2 / 55 (3.64%) |
| occurrences (all) | 0 | 1 | 2 |
| Muscular weakness | | | |
| subjects affected / exposed | 0 / 54 (0.00%) | 0 / 56 (0.00%) | 0 / 55 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal discomfort | | | |
| subjects affected / exposed | 0 / 54 (0.00%) | 0 / 56 (0.00%) | 0 / 55 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal stiffness | | | |
| subjects affected / exposed | 0 / 54 (0.00%) | 0 / 56 (0.00%) | 1 / 55 (1.82%) |
| occurrences (all) | 0 | 0 | 1 |
| Pain in jaw | | | |
| subjects affected / exposed | 0 / 54 (0.00%) | 0 / 56 (0.00%) | 0 / 55 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infections and infestations | | | |
| Cellulitis | | | |
| subjects affected / exposed | 1 / 54 (1.85%) | 0 / 56 (0.00%) | 0 / 55 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Clostridium difficile infection | | | |
| subjects affected / exposed | 0 / 54 (0.00%) | 0 / 56 (0.00%) | 0 / 55 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Folliculitis | | | |
| subjects affected / exposed | 0 / 54 (0.00%) | 1 / 56 (1.79%) | 1 / 55 (1.82%) |
| occurrences (all) | 0 | 1 | 1 |

| | | | |
|--|---------------------|---------------------|---------------------|
| Gastroenteritis subjects affected / exposed occurrences (all) | 0 / 54 (0.00%) 0 | 0 / 56 (0.00%) 0 | 0 / 55 (0.00%) 0 |
| Nasopharyngitis subjects affected / exposed occurrences (all) | 2 / 54 (3.70%) 2 | 2 / 56 (3.57%) 3 | 2 / 55 (3.64%) 2 |
| Rhinitis subjects affected / exposed occurrences (all) | 0 / 54 (0.00%) 0 | 0 / 56 (0.00%) 0 | 0 / 55 (0.00%) 0 |
| Sinusitis subjects affected / exposed occurrences (all) | 0 / 54 (0.00%) 0 | 3 / 56 (5.36%) 3 | 0 / 55 (0.00%) 0 |
| Urinary tract infection subjects affected / exposed occurrences (all) | 2 / 54 (3.70%) 2 | 2 / 56 (3.57%) 2 | 0 / 55 (0.00%) 0 |
| Metabolism and nutrition disorders Decreased appetite subjects affected / exposed occurrences (all) | 0 / 54 (0.00%) 0 | 0 / 56 (0.00%) 0 | 1 / 55 (1.82%) 1 |
| Fluid retention subjects affected / exposed occurrences (all) | 0 / 54 (0.00%) 0 | 0 / 56 (0.00%) 0 | 1 / 55 (1.82%) 1 |
| Hyperglycaemia subjects affected / exposed occurrences (all) | 0 / 54 (0.00%) 0 | 4 / 56 (7.14%) 4 | 1 / 55 (1.82%) 1 |

| Non-serious adverse events | Double-Blind Maintenance Andecaliximab Q2W | Double-Blind Maintenance Andecaliximab QW | Double-Blind Maintenance Placebo |
|---|--|---|-------------------------------------|
| Total subjects affected by non-serious adverse events subjects affected / exposed | 12 / 20 (60.00%) | 12 / 16 (75.00%) | 13 / 18 (72.22%) |
| Vascular disorders Hypertension subjects affected / exposed occurrences (all) | 0 / 20 (0.00%) 0 | 1 / 16 (6.25%) 1 | 0 / 18 (0.00%) 0 |
| General disorders and administration site conditions Fatigue | | | |

| | | | |
|--|----------------|----------------|-----------------|
| subjects affected / exposed | 1 / 20 (5.00%) | 1 / 16 (6.25%) | 2 / 18 (11.11%) |
| occurrences (all) | 1 | 1 | 1 |
| Feeling hot | | | |
| subjects affected / exposed | 0 / 20 (0.00%) | 0 / 16 (0.00%) | 1 / 18 (5.56%) |
| occurrences (all) | 0 | 0 | 1 |
| Influenza like illness | | | |
| subjects affected / exposed | 1 / 20 (5.00%) | 0 / 16 (0.00%) | 1 / 18 (5.56%) |
| occurrences (all) | 1 | 0 | 1 |
| Injection site bruising | | | |
| subjects affected / exposed | 0 / 20 (0.00%) | 0 / 16 (0.00%) | 0 / 18 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Injection site erythema | | | |
| subjects affected / exposed | 0 / 20 (0.00%) | 1 / 16 (6.25%) | 0 / 18 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Injection site hypersensitivity | | | |
| subjects affected / exposed | 1 / 20 (5.00%) | 0 / 16 (0.00%) | 0 / 18 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Peripheral swelling | | | |
| subjects affected / exposed | 0 / 20 (0.00%) | 0 / 16 (0.00%) | 1 / 18 (5.56%) |
| occurrences (all) | 0 | 0 | 1 |
| Pyrexia | | | |
| subjects affected / exposed | 1 / 20 (5.00%) | 0 / 16 (0.00%) | 1 / 18 (5.56%) |
| occurrences (all) | 1 | 0 | 1 |
| Thirst | | | |
| subjects affected / exposed | 0 / 20 (0.00%) | 1 / 16 (6.25%) | 0 / 18 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Immune system disorders | | | |
| Hypersensitivity | | | |
| subjects affected / exposed | 1 / 20 (5.00%) | 0 / 16 (0.00%) | 0 / 18 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Reproductive system and breast disorders | | | |
| Menstrual disorder | | | |
| subjects affected / exposed | 0 / 20 (0.00%) | 0 / 16 (0.00%) | 1 / 18 (5.56%) |
| occurrences (all) | 0 | 0 | 1 |
| Uterine prolapse | | | |

| | | | |
|--|---------------------|---------------------|---------------------|
| subjects affected / exposed occurrences (all) | 0 / 20 (0.00%) 0 | 1 / 16 (6.25%) 1 | 0 / 18 (0.00%) 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Cough | | | |
| subjects affected / exposed | 0 / 20 (0.00%) | 2 / 16 (12.50%) | 0 / 18 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Dyspnoea | | | |
| subjects affected / exposed | 0 / 20 (0.00%) | 1 / 16 (6.25%) | 0 / 18 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Upper respiratory tract inflammation | | | |
| subjects affected / exposed | 1 / 20 (5.00%) | 0 / 16 (0.00%) | 0 / 18 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Psychiatric disorders | | | |
| Depression | | | |
| subjects affected / exposed | 0 / 20 (0.00%) | 0 / 16 (0.00%) | 1 / 18 (5.56%) |
| occurrences (all) | 0 | 0 | 1 |
| Investigations | | | |
| Blood creatine phosphokinase increased | | | |
| subjects affected / exposed | 1 / 20 (5.00%) | 0 / 16 (0.00%) | 0 / 18 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Haemoglobin decreased | | | |
| subjects affected / exposed | 1 / 20 (5.00%) | 0 / 16 (0.00%) | 0 / 18 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Lymphocyte count decreased | | | |
| subjects affected / exposed | 1 / 20 (5.00%) | 0 / 16 (0.00%) | 0 / 18 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hypophosphataemia | | | |
| subjects affected / exposed | 0 / 20 (0.00%) | 2 / 16 (12.50%) | 0 / 18 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Iron deficiency | | | |
| subjects affected / exposed | 1 / 20 (5.00%) | 1 / 16 (6.25%) | 0 / 18 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Injury, poisoning and procedural complications | | | |
| Injection related reaction | | | |

| | | | |
|---|----------------------|----------------------|----------------------|
| subjects affected / exposed occurrences (all) | 0 / 20 (0.00%) 0 | 0 / 16 (0.00%) 0 | 1 / 18 (5.56%) 1 |
| Radius fracture subjects affected / exposed occurrences (all) | 1 / 20 (5.00%) 1 | 0 / 16 (0.00%) 0 | 0 / 18 (0.00%) 0 |
| Nervous system disorders | | | |
| Dizziness subjects affected / exposed occurrences (all) | 0 / 20 (0.00%) 0 | 1 / 16 (6.25%) 1 | 2 / 18 (11.11%) 2 |
| Headache subjects affected / exposed occurrences (all) | 0 / 20 (0.00%) 0 | 2 / 16 (12.50%) 2 | 1 / 18 (5.56%) 1 |
| Lethargy subjects affected / exposed occurrences (all) | 0 / 20 (0.00%) 0 | 0 / 16 (0.00%) 0 | 1 / 18 (5.56%) 1 |
| Polyneuropathy subjects affected / exposed occurrences (all) | 0 / 20 (0.00%) 0 | 1 / 16 (6.25%) 1 | 0 / 18 (0.00%) 0 |
| Sciatica subjects affected / exposed occurrences (all) | 1 / 20 (5.00%) 1 | 0 / 16 (0.00%) 0 | 0 / 18 (0.00%) 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia subjects affected / exposed occurrences (all) | 3 / 20 (15.00%) 3 | 1 / 16 (6.25%) 1 | 0 / 18 (0.00%) 0 |
| Thrombocytosis subjects affected / exposed occurrences (all) | 1 / 20 (5.00%) 1 | 0 / 16 (0.00%) 0 | 0 / 18 (0.00%) 0 |
| Ear and labyrinth disorders | | | |
| Ear discomfort subjects affected / exposed occurrences (all) | 0 / 20 (0.00%) 0 | 0 / 16 (0.00%) 0 | 1 / 18 (5.56%) 1 |
| Eye disorders | | | |
| Dry eye subjects affected / exposed occurrences (all) | 0 / 20 (0.00%) 0 | 0 / 16 (0.00%) 0 | 0 / 18 (0.00%) 0 |
| Gastrointestinal disorders | | | |

| | | | |
|-----------------------------|-----------------|----------------|-----------------|
| Abdominal discomfort | | | |
| subjects affected / exposed | 0 / 20 (0.00%) | 0 / 16 (0.00%) | 1 / 18 (5.56%) |
| occurrences (all) | 0 | 0 | 1 |
| Abdominal distension | | | |
| subjects affected / exposed | 0 / 20 (0.00%) | 1 / 16 (6.25%) | 1 / 18 (5.56%) |
| occurrences (all) | 0 | 1 | 2 |
| Abdominal pain | | | |
| subjects affected / exposed | 1 / 20 (5.00%) | 0 / 16 (0.00%) | 1 / 18 (5.56%) |
| occurrences (all) | 1 | 0 | 1 |
| Colitis ulcerative | | | |
| subjects affected / exposed | 2 / 20 (10.00%) | 1 / 16 (6.25%) | 4 / 18 (22.22%) |
| occurrences (all) | 2 | 1 | 4 |
| Dyschezia | | | |
| subjects affected / exposed | 0 / 20 (0.00%) | 1 / 16 (6.25%) | 0 / 18 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Frequent bowel movements | | | |
| subjects affected / exposed | 0 / 20 (0.00%) | 1 / 16 (6.25%) | 0 / 18 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Haematochezia | | | |
| subjects affected / exposed | 1 / 20 (5.00%) | 1 / 16 (6.25%) | 0 / 18 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Haemorrhoids | | | |
| subjects affected / exposed | 0 / 20 (0.00%) | 1 / 16 (6.25%) | 1 / 18 (5.56%) |
| occurrences (all) | 0 | 1 | 1 |
| Inguinal hernia | | | |
| subjects affected / exposed | 0 / 20 (0.00%) | 1 / 16 (6.25%) | 0 / 18 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Mouth ulceration | | | |
| subjects affected / exposed | 1 / 20 (5.00%) | 0 / 16 (0.00%) | 0 / 18 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Nausea | | | |
| subjects affected / exposed | 0 / 20 (0.00%) | 0 / 16 (0.00%) | 0 / 18 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rectal haemorrhage | | | |
| subjects affected / exposed | 0 / 20 (0.00%) | 0 / 16 (0.00%) | 1 / 18 (5.56%) |
| occurrences (all) | 0 | 0 | 1 |

| | | | |
|---|----------------|-----------------|----------------|
| Skin and subcutaneous tissue disorders | | | |
| Acne | | | |
| subjects affected / exposed | 0 / 20 (0.00%) | 2 / 16 (12.50%) | 0 / 18 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Alopecia | | | |
| subjects affected / exposed | 0 / 20 (0.00%) | 1 / 16 (6.25%) | 0 / 18 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Dry skin | | | |
| subjects affected / exposed | 0 / 20 (0.00%) | 0 / 16 (0.00%) | 1 / 18 (5.56%) |
| occurrences (all) | 0 | 0 | 1 |
| Erythema | | | |
| subjects affected / exposed | 0 / 20 (0.00%) | 1 / 16 (6.25%) | 0 / 18 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Erythema nodosum | | | |
| subjects affected / exposed | 1 / 20 (5.00%) | 0 / 16 (0.00%) | 0 / 18 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Night sweats | | | |
| subjects affected / exposed | 1 / 20 (5.00%) | 1 / 16 (6.25%) | 0 / 18 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Onychoclasia | | | |
| subjects affected / exposed | 0 / 20 (0.00%) | 1 / 16 (6.25%) | 0 / 18 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Psoriasis | | | |
| subjects affected / exposed | 0 / 20 (0.00%) | 1 / 16 (6.25%) | 0 / 18 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Rash | | | |
| subjects affected / exposed | 1 / 20 (5.00%) | 0 / 16 (0.00%) | 1 / 18 (5.56%) |
| occurrences (all) | 1 | 0 | 1 |
| Skin lesion | | | |
| subjects affected / exposed | 0 / 20 (0.00%) | 1 / 16 (6.25%) | 0 / 18 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Renal and urinary disorders | | | |
| Haematuria | | | |
| subjects affected / exposed | 1 / 20 (5.00%) | 0 / 16 (0.00%) | 0 / 18 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Musculoskeletal and connective tissue disorders | | | |

| | | | |
|---------------------------------|----------------|-----------------|-----------------|
| Arthralgia | | | |
| subjects affected / exposed | 1 / 20 (5.00%) | 3 / 16 (18.75%) | 3 / 18 (16.67%) |
| occurrences (all) | 1 | 3 | 3 |
| Back pain | | | |
| subjects affected / exposed | 0 / 20 (0.00%) | 1 / 16 (6.25%) | 0 / 18 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Muscle spasms | | | |
| subjects affected / exposed | 0 / 20 (0.00%) | 1 / 16 (6.25%) | 2 / 18 (11.11%) |
| occurrences (all) | 0 | 1 | 2 |
| Muscular weakness | | | |
| subjects affected / exposed | 0 / 20 (0.00%) | 1 / 16 (6.25%) | 0 / 18 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Musculoskeletal discomfort | | | |
| subjects affected / exposed | 0 / 20 (0.00%) | 0 / 16 (0.00%) | 1 / 18 (5.56%) |
| occurrences (all) | 0 | 0 | 1 |
| Musculoskeletal stiffness | | | |
| subjects affected / exposed | 0 / 20 (0.00%) | 0 / 16 (0.00%) | 1 / 18 (5.56%) |
| occurrences (all) | 0 | 0 | 1 |
| Pain in jaw | | | |
| subjects affected / exposed | 0 / 20 (0.00%) | 0 / 16 (0.00%) | 1 / 18 (5.56%) |
| occurrences (all) | 0 | 0 | 1 |
| Infections and infestations | | | |
| Cellulitis | | | |
| subjects affected / exposed | 1 / 20 (5.00%) | 0 / 16 (0.00%) | 0 / 18 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Clostridium difficile infection | | | |
| subjects affected / exposed | 1 / 20 (5.00%) | 0 / 16 (0.00%) | 0 / 18 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Folliculitis | | | |
| subjects affected / exposed | 0 / 20 (0.00%) | 1 / 16 (6.25%) | 0 / 18 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Gastroenteritis | | | |
| subjects affected / exposed | 0 / 20 (0.00%) | 0 / 16 (0.00%) | 0 / 18 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasopharyngitis | | | |

| | | | |
|--|---------------------|----------------------|----------------------|
| subjects affected / exposed occurrences (all) | 0 / 20 (0.00%) 0 | 2 / 16 (12.50%) 3 | 2 / 18 (11.11%) 2 |
| Rhinitis | | | |
| subjects affected / exposed occurrences (all) | 0 / 20 (0.00%) 0 | 1 / 16 (6.25%) 1 | 0 / 18 (0.00%) 0 |
| Sinusitis | | | |
| subjects affected / exposed occurrences (all) | 0 / 20 (0.00%) 0 | 1 / 16 (6.25%) 1 | 0 / 18 (0.00%) 0 |
| Urinary tract infection | | | |
| subjects affected / exposed occurrences (all) | 1 / 20 (5.00%) 1 | 1 / 16 (6.25%) 1 | 0 / 18 (0.00%) 0 |
| Metabolism and nutrition disorders | | | |
| Decreased appetite | | | |
| subjects affected / exposed occurrences (all) | 0 / 20 (0.00%) 0 | 0 / 16 (0.00%) 0 | 1 / 18 (5.56%) 1 |
| Fluid retention | | | |
| subjects affected / exposed occurrences (all) | 0 / 20 (0.00%) 0 | 0 / 16 (0.00%) 0 | 1 / 18 (5.56%) 1 |
| Hyperglycaemia | | | |
| subjects affected / exposed occurrences (all) | 0 / 20 (0.00%) 0 | 1 / 16 (6.25%) 1 | 0 / 18 (0.00%) 0 |

| Non-serious adverse events | Open-Label Andecaliximab QW from Andecaliximab Q2W | Open-Label Andecaliximab QW from Andecaliximab QW | Open-Label Andecaliximab QW from Placebo |
|--|---|--|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 9 / 32 (28.13%) | 6 / 35 (17.14%) | 12 / 34 (35.29%) |
| Vascular disorders | | | |
| Hypertension | | | |
| subjects affected / exposed occurrences (all) | 0 / 32 (0.00%) 0 | 0 / 35 (0.00%) 0 | 0 / 34 (0.00%) 0 |
| General disorders and administration site conditions | | | |
| Fatigue | | | |
| subjects affected / exposed occurrences (all) | 0 / 32 (0.00%) 2 | 0 / 35 (0.00%) 0 | 1 / 34 (2.94%) 1 |
| Feeling hot | | | |

| | | | |
|---|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 0 / 34 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Influenza like illness | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 0 / 34 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Injection site bruising | | | |
| subjects affected / exposed | 1 / 32 (3.13%) | 0 / 35 (0.00%) | 0 / 34 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Injection site erythema | | | |
| subjects affected / exposed | 1 / 32 (3.13%) | 0 / 35 (0.00%) | 0 / 34 (0.00%) |
| occurrences (all) | 5 | 0 | 0 |
| Injection site hypersensitivity | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 0 / 34 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Peripheral swelling | | | |
| subjects affected / exposed | 1 / 32 (3.13%) | 0 / 35 (0.00%) | 1 / 34 (2.94%) |
| occurrences (all) | 1 | 0 | 1 |
| Pyrexia | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 0 / 34 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Thirst | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 0 / 34 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Immune system disorders | | | |
| Hypersensitivity | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 0 / 34 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Reproductive system and breast disorders | | | |
| Menstrual disorder | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 0 / 34 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Uterine prolapse | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 0 / 34 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Respiratory, thoracic and mediastinal disorders | | | |

| | | | |
|--|---------------------|---------------------|---------------------|
| Cough subjects affected / exposed occurrences (all) | 1 / 32 (3.13%) 1 | 0 / 35 (0.00%) 0 | 0 / 34 (0.00%) 0 |
| Dyspnoea subjects affected / exposed occurrences (all) | 0 / 32 (0.00%) 0 | 0 / 35 (0.00%) 0 | 0 / 34 (0.00%) 0 |
| Upper respiratory tract inflammation subjects affected / exposed occurrences (all) | 0 / 32 (0.00%) 0 | 0 / 35 (0.00%) 0 | 0 / 34 (0.00%) 0 |
| Psychiatric disorders Depression subjects affected / exposed occurrences (all) | 0 / 32 (0.00%) 0 | 0 / 35 (0.00%) 0 | 1 / 34 (2.94%) 1 |
| Investigations Blood creatine phosphokinase increased subjects affected / exposed occurrences (all) | 0 / 32 (0.00%) 0 | 0 / 35 (0.00%) 0 | 0 / 34 (0.00%) 0 |
| Haemoglobin decreased subjects affected / exposed occurrences (all) | 0 / 32 (0.00%) 0 | 0 / 35 (0.00%) 0 | 0 / 34 (0.00%) 0 |
| Lymphocyte count decreased subjects affected / exposed occurrences (all) | 0 / 32 (0.00%) 0 | 0 / 35 (0.00%) 0 | 0 / 34 (0.00%) 0 |
| Hypophosphataemia subjects affected / exposed occurrences (all) | 1 / 32 (3.13%) 1 | 0 / 35 (0.00%) 0 | 0 / 34 (0.00%) 0 |
| Iron deficiency subjects affected / exposed occurrences (all) | 0 / 32 (0.00%) 0 | 1 / 35 (2.86%) 1 | 0 / 34 (0.00%) 0 |
| Injury, poisoning and procedural complications Injection related reaction subjects affected / exposed occurrences (all) | 0 / 32 (0.00%) 0 | 0 / 35 (0.00%) 0 | 0 / 34 (0.00%) 0 |
| Radius fracture subjects affected / exposed occurrences (all) | 0 / 32 (0.00%) 0 | 0 / 35 (0.00%) 0 | 0 / 34 (0.00%) 0 |

| | | | |
|--------------------------------------|----------------|----------------|----------------|
| Nervous system disorders | | | |
| Dizziness | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 0 / 34 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Headache | | | |
| subjects affected / exposed | 1 / 32 (3.13%) | 0 / 35 (0.00%) | 0 / 34 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Lethargy | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 0 / 34 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Polyneuropathy | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 0 / 34 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sciatica | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 0 / 34 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 1 / 35 (2.86%) | 3 / 34 (8.82%) |
| occurrences (all) | 0 | 1 | 3 |
| Thrombocytosis | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 0 / 34 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ear and labyrinth disorders | | | |
| Ear discomfort | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 0 / 34 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye disorders | | | |
| Dry eye | | | |
| subjects affected / exposed | 1 / 32 (3.13%) | 0 / 35 (0.00%) | 0 / 34 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Gastrointestinal disorders | | | |
| Abdominal discomfort | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 1 / 34 (2.94%) |
| occurrences (all) | 0 | 0 | 1 |
| Abdominal distension | | | |

| | | | |
|--|----------------|----------------|----------------|
| subjects affected / exposed | 1 / 32 (3.13%) | 0 / 35 (0.00%) | 0 / 34 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Abdominal pain | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 1 / 34 (2.94%) |
| occurrences (all) | 0 | 0 | 1 |
| Colitis ulcerative | | | |
| subjects affected / exposed | 1 / 32 (3.13%) | 1 / 35 (2.86%) | 3 / 34 (8.82%) |
| occurrences (all) | 1 | 1 | 4 |
| Dyschezia | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 0 / 34 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Frequent bowel movements | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 0 / 34 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haematochezia | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 0 / 34 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Haemorrhoids | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 0 / 34 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Inguinal hernia | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 0 / 34 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Mouth ulceration | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 0 / 34 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nausea | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 2 / 35 (5.71%) | 0 / 34 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Rectal haemorrhage | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 1 / 34 (2.94%) |
| occurrences (all) | 0 | 0 | 1 |
| Skin and subcutaneous tissue disorders | | | |
| Acne | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 0 / 34 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|---|----------------|----------------|----------------|
| Alopecia | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 1 / 34 (2.94%) |
| occurrences (all) | 0 | 0 | 1 |
| Dry skin | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 0 / 34 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Erythema | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 0 / 34 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Erythema nodosum | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 0 / 34 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Night sweats | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 0 / 34 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Onychoclasia | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 0 / 34 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Psoriasis | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 0 / 34 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rash | | | |
| subjects affected / exposed | 1 / 32 (3.13%) | 0 / 35 (0.00%) | 0 / 34 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Skin lesion | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 0 / 34 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Renal and urinary disorders | | | |
| Haematuria | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 0 / 34 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 2 / 35 (5.71%) | 1 / 34 (2.94%) |
| occurrences (all) | 0 | 2 | 1 |
| Back pain | | | |

| | | | |
|---------------------------------|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 1 / 34 (2.94%) |
| occurrences (all) | 0 | 0 | 1 |
| Muscle spasms | | | |
| subjects affected / exposed | 1 / 32 (3.13%) | 0 / 35 (0.00%) | 0 / 34 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Muscular weakness | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 0 / 34 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal discomfort | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 0 / 34 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Musculoskeletal stiffness | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 0 / 34 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Pain in jaw | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 0 / 34 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infections and infestations | | | |
| Cellulitis | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 0 / 34 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Clostridium difficile infection | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 0 / 34 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Folliculitis | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 0 / 34 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastroenteritis | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 2 / 34 (5.88%) |
| occurrences (all) | 0 | 0 | 2 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 1 / 32 (3.13%) | 1 / 35 (2.86%) | 0 / 34 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Rhinitis | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 0 / 34 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

| | | | |
|------------------------------------|----------------|----------------|----------------|
| Sinusitis | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 1 / 35 (2.86%) | 1 / 34 (2.94%) |
| occurrences (all) | 0 | 3 | 1 |
| Urinary tract infection | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 1 / 34 (2.94%) |
| occurrences (all) | 0 | 0 | 1 |
| Metabolism and nutrition disorders | | | |
| Decreased appetite | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 0 / 34 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Fluid retention | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 0 / 34 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Hyperglycaemia | | | |
| subjects affected / exposed | 0 / 32 (0.00%) | 0 / 35 (0.00%) | 0 / 34 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|------------------|---|
| 29 May 2015 | <ol style="list-style-type: none">1. Clarified that physician's global assessment is measured at baseline and part of eligibility criteria2. Updated immunomodulator and vedolizumab minimum duration of treatment prior therapy as part of the eligibility criteria3. Updated steroid tapering to include a reduction range from 2.5 mg/week to 5 mg/week4. Clarified that albumin is analyzed as part of the chemistry panel |
| 27 October 2015 | <ol style="list-style-type: none">1. Added evaluation of sustained MCS clinical remission, and definition of sustained MCS clinical remission, under secondary objectives and endpoints2. Added evaluation of corticosteroid-free EBS clinical remission for at least 24 weeks prior to Week 52 under secondary objectives and endpoints3. Added a 70% TNF-α antagonist treatment cap to Cohort 2 open-label induction phase enrollment and removed cap from Cohort 2 blinded maintenance phase randomization4. Clarified golimumab dose/exposure in inclusion criteria5. Added treatment with tacrolimus and apheresis therapy to exclusion criteria and prohibited concomitant medication6. Specified that compliance phone call for stool frequency and rectal bleeding documentation should occur approximately 4 days after the screening visit7. Clarified that if a colonoscopy was performed at screening, a flexible sigmoidoscopy was not required8. Clarified that 3 biopsy samples must be collected at screening9. Added instruction to remind subjects to complete documentation of dosing log for subjects dosing at home10. Removed lack of efficacy from the list of AEs/serious adverse events (SAEs) to be collected11. Added AEs arising from occupational exposure to special situation reporting requirements12. Added collection of microbiome sample to study procedures table13. Applied stopping rules and follow-up visit requirement for disease worsening to open-label maintenance phase14. Clarified that study medication may be discontinued if a subject experiences exclusionary medical conditions |
| 29 February 2016 | <ol style="list-style-type: none">1. Added an extended treatment phase for subjects completing Cohort 1 and Cohort 2 and described timing of study visits, procedures, and analyses specific to this phase2. Clarified randomization stratification3. Added methotrexate as an approved immunomodulator and concomitant UC medication in the inclusion criteria4. Clarified screening of new subjects once the 70% cap on prior TNF-α antagonist therapy was met5. Clarified inclusion criteria to specify that females were to be nonpregnant and nonlactating6. Clarified collection time points for the optional PK substudy7. Clarified screening visit assessments |

| | |
|--------------|--|
| 13 June 2016 | <ol style="list-style-type: none"> 1. Clarified disease worsening discontinuation criteria as it related to subject discontinuation and follow-up requirements during the open-label maintenance or extended treatment phase 2. Updated the name and contact information for the Gilead study director and medical monitor 3. Revised inclusion criteria to specify subject requirements for prior immunomodulator, TNF-α agonist, or vedolizumab therapy in order to clarify criteria for an inadequate clinical response to these therapies 4. Revised exclusion criteria to exclude subjects with known hypersensitivity to any components of the investigational medicinal product 5. Made exclusionary laboratory parameters for liver panel values more restrictive (> 2 times the upper limit of the normal range [ULN]) 6. Revised exclusion criteria to clarify temporal restriction for prior treatment with tacrolimus and apheresis 7. Clarified that subjects requiring dose increases to allowed UC medications during the induction phase would be discontinued from the study 8. Defined mucosal healing for the purposes of study evaluation 9. Clarified UC medications allowed during the open-label maintenance and extended treatment phases of the study 10. Specified that investigational drugs for the treatment of UC were prohibited during the study 11. Specified clinical laboratory analytes to be evaluated and antibody/antigen tests to be conducted |
|--------------|--|

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? Yes

| Date | Interruption | Restart date |
|-------------------|--|--------------|
| 21 September 2016 | After the first 150 subjects completed the 8-week induction phase, the data monitoring committee (DMC) for this Study conducted a protocol-specified interim analysis. After review, the DMC recommended that the study be terminated due to meeting the prespecified futility and efficacy criteria. Effective 21 September 2016, Study GS-US-326-1100 was terminated. Part B of Cohort 1 and Cohort 2 were not enrolled. | - |

Notes:

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

The DMC recommended that the study be terminated due to meeting the prespecified futility & efficacy criteria. Due to termination of the study, no formal statistical testing was planned for the final analysis.

Notes: